SCHEMBL4932652

SCHEMBL4932652

O=C(Nc1scnc1C(=O)O)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KDR P35968 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK10 P53779 1/20 0.48
HCAR3 P49019 1/20 0.47
MAPT P10636 2/20 0.47
PTPN5 P54829 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
SCD O00767 1/20 0.47
P4HTM Q9NXG6 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4902010 0.78 MEN1 (0.50) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL4935840 0.78 KMT2A (0.52) KDM4ERAB9AMEN1KMT2AALDH1A1
SCHEMBL24441381 0.77 HSD17B13 (0.58)
SCHEMBL27087463 0.77 HSD17B10 (0.51) KDM4ENPC1RAB9AMAPTMEN1
SCHEMBL30560835 0.76 KCNK3 (0.40) NPC1RAB9AKDRMEN1KMT2A
SCHEMBL2826686 0.76 KDM4E (0.54) KDM4EHCAR3
SCHEMBL7842661 0.76 KDM4E (0.54) KDM4ENPC1RAB9AMAPTSCD
SCHEMBL31062630 0.74 POLB (0.55) MAPTALDH1A1GAAHTT
SCHEMBL4936608 0.73 KDM4E (0.55) KDM4ERAB9AMAPTMEN1KMT2A
SCHEMBL2830086 0.73 NPC1 (0.56) NPC1RAB9AMAPTPTPN5NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US claimed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP claimed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO claimed
US-20080167309-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS, LTD. (UK) 2008-07-10 US disclosed
EP-1781647-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006008545-A2 THIAZOLE AND ISOTHIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167309-A1 Pharmaceutical Compounds CCNO, CDK2, CDK1 KDM4E 1029/4885NPC1 1595/4885RAB9A 3089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.